Amgen reports positive results for treatment of IgG4-RD
Drug Discovery World
JULY 5, 2024
Amgen has reported positive topline results from its randomised, double-blind, multicentre, placebo-controlled Phase III clinical trial evaluating the efficacy and safety of its treatment for Immunoglobulin G4-related disease (IgG4-RD). ” Amgen is now planning to file for approval in the US following results on the MITIGATE study. .”
Let's personalize your content